Melanotan I Research Overview (also known as MT-1, Afamelanotide)
A synthetic analog of alpha-MSH studied for its ability to stimulate melanin production, producing UV-protective skin pigmentation with minimal effects on libido or appetite compared to MT-2. Research interest includes pigmentation regulation and UV-exposure response studies.
What Is Melanotan I?
Melanotan I (Afamelanotide) is a synthetic linear analog of α-Melanocyte Stimulating Hormone (α-MSH), differing from the native 13-amino-acid hormone by a single substitution (Nle4, D-Phe7) that confers resistance to enzymatic degradation and significantly extends its activity duration. It binds MC1R on melanocytes, triggering melanin synthesis and natural skin darkening independent of UV exposure.
Mechanism and Clinical Approval
Melanotan I activates MC1R on melanocytes, initiating the cAMP signaling cascade that upregulates tyrosinase — the rate-limiting enzyme in melanin synthesis. Unlike UV-induced tanning (which causes DNA damage to trigger melanin production), Melanotan I stimulates melanin production directly without requiring mutagenic UV insult. Afamelanotide (Scenesse) received EMA approval in 2014 and FDA approval in 2019 for erythropoietic protoporphyria (EPP) — a rare genetic condition causing extreme photosensitivity — making it the first melanocortin agonist approved for human use.
Distinction from Melanotan II
Melanotan I is a linear peptide with primary MC1R selectivity. Melanotan II is a cyclic peptide with broader melanocortin receptor activity including MC3R and MC4R — producing additional effects on libido and appetite not shared by Melanotan I.
Quick Reference
| Literature-Reported Dose Range | 0.25-0.5mg per injection |
| Literature-Reported Frequency | 1-2x daily during loading phase |
| Literature-Reported Cycle Length | 2-4 weeks loading, then maintenance or break |
| Literature-Reported Washout | 4-8 weeks between cycles recommended |
| Storage | Powder: room temperature or refrigerated; Reconstituted: 2-8°C for up to 4 weeks |
| Sites Reported in Studies | SubQ: abdomen, thigh, upper arm (rotate sites) |
| Timing | Morning and evening injections, 6-8 hours apart |
Research Indications
Skin Health
Enhanced Tanning Response
Stimulates melanin production allowing deeper, longer-lasting tan with reduced UV exposure requirements
Photoprotection
Increased melanin density provides natural protection against UV damage and reduces sunburn susceptibility
Even Pigmentation
Promotes uniform melanin distribution reducing patchy tanning and providing consistent skin tone
Anti-Aging
UV Damage Prevention
Enhanced melanin acts as natural sunscreen reducing photoaging and UV-induced skin damage
Antioxidant Effects
Stimulated eumelanin provides cellular antioxidant protection against free radicals
Reduced Sun Exposure Need
Achieves desired tanning with less UV exposure, minimizing cumulative skin damage
Research
Melanocortin System Research
Tool for studying MC1R receptor function and melanin biosynthesis pathways
Photoprotection Studies
Research model for natural photoprotective mechanisms and UV damage prevention
Cosmetic Applications
Investigation of safe tanning methods and pigmentation enhancement techniques
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Initial Tanning (Light Skin) | 0.25mg | 2x daily | SubQ |
| Maintenance Tanning | 0.5mg | 1x daily | SubQ |
| Enhanced Pigmentation | 0.5mg | 2x daily | SubQ |
| Photoprotection Only | 0.25mg | 1x daily | SubQ |
Timing
Recommended administration window: morning and evening injections, 6-8 hours apart. Typical onset: initial darkening in 3-5 days, significant tanning in 1-2 weeks with UV exposure.
Peptide Interactions
Both target melanocortin receptors but Melanotan I has better safety profile and selectivity for MC1R. Should not be combined due to overlapping mechanisms and additive effects.
Melanotan I enhances tanning response to UV exposure, allowing deeper pigmentation with less sun exposure. Reduces required UV dose for tanning by approximately 50%.
Natural carotenoid provides additional photoprotection. No known interactions with Melanotan I. Can be used together for enhanced skin protection.
Retinoids increase skin photosensitivity while Melanotan I provides photoprotection. Monitor for skin reactions and adjust UV exposure accordingly.
Antibiotics, diuretics, and other photosensitizing drugs may increase UV sensitivity. Enhanced monitoring recommended when combining with Melanotan I.
Topical self-tanners work through different mechanisms (DHA) and can be used alongside Melanotan I for enhanced cosmetic appearance.
Reported Research Timeline
01Days 1–3 (reported in cited studies): possible mild nausea, facial flushing, reduced appetite
02Days 3–7 (reported in cited studies): initial skin darkening, increased pigmentation of moles and freckles
03Week 1–2 (reported in cited studies): noticeable tanning with minimal UV exposure, enhanced tanning response
04Week 2–4 (reported in cited studies): peak tanning effects, maintained pigmentation with reduced injection frequency
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Research peptide - not approved for human consumption, sold for research purposes only
Start with lower doses to assess individual tolerance and response
Monitor moles and skin changes - perform regular self-examinations
Use proper sterile injection technique to prevent infections
Maintain UV protection despite enhanced tanning - still risk of overexposure
Seek Medical Attention If:
Severe nausea, vomiting, or gastrointestinal distress lasting more than 24 hours
Rapid or concerning changes in moles, freckles, or existing pigmented lesions
Signs of injection site infection: persistent redness, swelling, warmth, or discharge
Unusual skin reactions: rashes, hives, or severe itching
Any signs of allergic reaction: difficulty breathing, facial swelling, severe dizziness
Quality Indicators
Verified Marker
Third-party laboratory testing
Reputable vendors provide HPLC purity testing and amino acid analysis confirming >98% purity
Verified Marker
Proper peptide storage
Lyophilized powder stable at room temperature during shipping, refrigerate upon arrival
Verified Marker
Clear reconstitution
Properly reconstituted Melanotan I should be completely clear and colorless without particles
Quality Concern
Premixed solutions
Avoid pre-mixed liquid Melanotan I as peptides degrade rapidly in solution without proper preservation
Acceptable Range
Tanning injection sites
Some vendors market nasal sprays or tanning injections - stick to research-grade lyophilized powder only
Verified Marker
Minimal side effects
High-quality Melanotan I should cause only mild nausea and flushing, not severe reactions
Research Citations
- Evaluation of melanotan-I, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study
Dorr, R.T., Lines, R., Levine, N., et al., 2004, Life Sciences - Pharmacokinetics of [Nle4,D-Phe7]-alpha-MSH in rats and humans
Ugwu, S.O., Blanchard, J., Dorr, R.T., et al., 1997, Peptides - Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization
Hadley, M.E., Dorr, R.T., 2006, Peptides - Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin
Levine, N., Sheftel, S.N., Eytan, T., et al., 1991, JAMA - Melanotan I reduces the incidence of acute and chronic UV-induced skin damage
Barnetson, R.S., Ooi, T.K., Zhuang, L., et al., 2006, British Journal of Dermatology - The melanocortin-1 receptor is a key regulator of human cutaneous pigmentation
Abdel-Malek, Z., Scott, M.C., Suzuki, I., et al., 2000, Pigment Cell Research - Skin pigmentation and pharmacokinetics of melanotan-I in humans
Ugwu SO, Blanchard J, Dorr RT, 1997, Biopharm Drug Dispos - Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization
Hadley ME, Dorr RT, 2006, Peptides
Research Focus
Tanning, Melanogenesis, Melanoma prevention, UV protection, Photoprotection
Verified Vendors Carrying Melanotan I
Frequently Asked Questions
What should researchers watch for with Melanotan I?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Melanotan I?
Days 1–3 (reported in cited studies): possible mild nausea, facial flushing, reduced appetite
How is Melanotan I typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →